Drug intelligence / Profile preview

QLS5132 + bevacizumab

Development stage: Unknown
Lead developer: Qilu Pharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

QLS5132 + bevacizumab is a combination therapy being developed by Qilu Pharmaceutical for the treatment of advanced solid tumors, including ovarian, gastric, endometrial, and non-small cell lung cancers. QLS5132 is an antibody-drug conjugate (ADC) consisting of a humanized anti-Claudin-6 (CLDN6) hIgG1 antibody conjugated to a proprietary topoisomerase-1 inhibitor (QLS6916) via a hydrophilic cleavable linker. Bevacizumab is a recombinant humanized monoclonal antibody that binds to and neutralizes vascular endothelial growth factor (VEGF), inhibiting angiogenesis. This combination aims to leverage the targeted cytotoxic effects of the CLDN6-directed ADC with the anti-angiogenic properties of bevacizumab to enhance anti-tumor efficacy in CLDN6-positive malignancies.

Targets

VEGFA (Vascular endothelial growth factor A)TOP1 (DNA Topoisomerase I)CLDN6 (Claudin-6)

Beyond the preview

Go deeper on QLS5132 + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLS5132 + bevacizumab.

Explore the full profile